What is Modulo Bio?
Modulo Bio operates at the intersection of advanced biotechnology and neurological science. Based in San Diego, the company is dedicated to decoding the complexities of the nervous system to develop innovative therapeutic solutions. By focusing on high-impact areas of human health, Modulo Bio has established itself as a key player in the biotech ecosystem, attracting interest from top-tier venture capital firms that prioritize long-term scientific breakthroughs over short-term gains. The company's strategic focus remains on bridging the gap between fundamental biological research and scalable healthcare solutions.
How much funding has Modulo Bio raised?
Modulo Bio has raised a total of $8M across 1 funding round:
Other Financing Round
$8M
Other Financing Round (2023): $8M with participation from Builders VC, Initialized Capital, and Bioverge
Key Investors in Modulo Bio
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions, supporting founders who tackle complex problems.
Initialized Capital
Initialized Capital is a venture capital firm dedicated to supporting seed stage founders across various sectors including enterprise SaaS, sustainability, health, and artificial intelligence.
Bioverge
Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life through deep domain expertise.
What's next for Modulo Bio?
With the recent influx of capital, Modulo Bio is expected to scale its research infrastructure and expand its team of scientific experts. The company's roadmap likely involves advancing its lead candidates through preclinical milestones, a move that will be essential for securing future institutional backing. As the firm transitions into a more mature stage of development, the focus will shift toward regulatory engagement and potential strategic partnerships that can facilitate the commercialization of its proprietary technologies. Investors will be closely monitoring the company's ability to translate its scientific insights into tangible clinical outcomes, which will be the primary driver for subsequent financing rounds.
See full Modulo Bio company page
